![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Valneva, Dynavax Inks $1.5 Billion COVID-19 Vaccine Supply Deal with UK
Valneva, Dynavax Inks $1.5 Billion COVID-19 Vaccine Supply Deal with UK
![UKflag.jpg](https://www.fdanews.com/ext/resources/test/Drug-Images4/UKflag.jpg?t=1586293848&width=430)
September 15, 2020
The UK government has signed a $1.5 billion agreement with Valneva for up to 190 million doses of the French company’s COVID-19 vaccine — enough to provide multiple doses to the UK’s population of almost 68 million.
Under the agreement, the UK will pay $558 million for 60 million doses of VLA2001, which will be supplied in the second half of 2021. The deal includes an option to purchase 40 million more doses in 2022 and an additional 30 million to 90 million doses between 2023-2025.
Berkeley, Calif.-based Dynavax, which is a party to the agreement, will supply 190 million doses of its CpG1018 adjuvant for the vaccine.
Upcoming Events
-
21Oct